Although the effect of arylpiperazines on invasion and metastasis has not been studied yet, the inhibition of FATP1 with arylpiperazines interfered with the uptake of fatty acids and cell viability of breast cancer cells (175). This evidence concerns the gene SLC27A1 and breast carcinoma.